Company Analysis
Sign in

Insmed Incorporated (INSM)

Nasdaq: INSM · Pharmaceutical Preparations · Bridgewater, NJ · filing with the SEC since 2000
Full chart Alerts Compare
Grade6.0
◀ Past 7.0● Present 5.4▶ Future 5.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

111 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Insmed Incorporated’s names, not what it holds today.

Patents granted
111
110 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
4
Against 6 in 2024 and 4 in 2023
Applications published
130
13 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals17
Organic fine chemistry2
Computer technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Insmed Incorporated its own name
US, as the owner printed on each patent
64 granted
37 published
Insmed Incorporated its own name
named as the applicant on its applications, in US
0 granted
91 published
Celtrix Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
47 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,479,837Reversible DPP1 inhibitors and uses thereofOrganic fine chemistryInsmed Incorporated
Aug 5, 202512,377,114Methods for treating pulmonary non-tuberculous mycobacterial infectionsPharmaceuticalsInsmed Incorporated
May 6, 202512,290,600Methods for continuous manufacture of liposomal drug productsPharmaceuticalsInsmed Incorporated
Jan 21, 202512,201,725Dry powder compositions of treprostinil prodrugs and methods of use thereofPharmaceuticalsInsmed Incorporated
Dec 17, 202412,168,022Methods for treating pulmonary non-tuberculous mycobacterial infectionsPharmaceuticalsInsmed Incorporated
Dec 17, 202412,168,021Methods for treating pulmonary non-tuberculous mycobacterial infectionsPharmaceuticalsInsmed Incorporated
Oct 1, 202412,104,186Deimmunized lysostaphin and methods of usePharmaceuticalsInsmed Incorporated
Jun 25, 202412,016,873Methods for treating pulmonary non-tuberculous mycobacterial infectionsPharmaceuticalsInsmed Incorporated
Jun 4, 202411,998,553Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritisPharmaceuticalsInsmed Incorporated
Jan 2, 202411,857,597Lipo-glycopeptide cleavable derivatives and uses thereofPharmaceuticalsInsmed Incorporated
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325574METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSPharmaceuticalsInsmed Incorporated
Oct 23, 20252025/0325481METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTSPharmaceuticalsInsmed Incorporated
Jul 17, 20252025/0228870CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASISPharmaceuticalsInsmed Incorporated
Jul 10, 20252025/0223284REVERSIBLE DPP1 INHIBITORS AND USES THEREOFOrganic fine chemistryInsmed Incorporated · patent 12,479,837 granted from it
Jun 5, 20252025/0177306DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOFPharmaceuticalsInsmed Incorporated
May 22, 20252025/0162982METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGSOrganic fine chemistryInsmed Incorporated
May 8, 20252025/0144116CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVAPharmaceuticalsInsmed Incorporated
May 1, 20252025/0135028TUNABLE POLYMERIC NANOPARTICLES FOR TARGETED AND SUSTAINED DELIVERY OF GLYCOPEPTIDE ANTIBIOTICSMacromolecular chemistry, polymersInsmed Incorporated
Mar 13, 20252025/0082570COMBINATION THERAPY FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASEPharmaceuticalsInsmed Incorporated
Feb 20, 20252025/0057863METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSPharmaceuticalsInsmed Incorporated
What it applied for, 2024 to 2025: Pharmaceuticals 18 · Organic fine chemistry 2 · Medical technology 1 · Macromolecular chemistry, polymers 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton INSM · research, not advice